Navigation Links
SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Date:10/29/2008

FRESNO, Calif., Oct. 29 /PRNewswire/ -- Cypress Systems, Inc., a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results -- that were announced yesterday -- used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at http://www.cypsystems.com.

The results of the SELECT TRIAL are consistent with previous animal studies. For example, Dr. David McCormick at the Experimental Toxicology and Carcinogenesis Division, IIT Research Institute in Chicago found no effects with selenomethionine supplementation on the prevention of prostate cancer in rats (Eur Urol 1999;35:464-467).

Such negative findings have not been observed for other forms of selenium. For example, research at Purdue University found SelenoExcell(R) High-Selenium Yeast to be more effective than selenomethionine in the reducing DNA damage in canine prostate cells (Waters et al, J. Natl Cancer Inst (2003); 95:237-240). Researchers at the University of Arizona and Cornell University reported in the Journal of American Medical Association (Clark et al, JAMA, Dec. 25, 1996-vol. 276, No.24).) that regular use of 200 micrograms per day of selenium in the form of SelenoExcell(R) reduced the incidences of lung, colon, and prostate cancers by 50-63%. Researchers at the Penn State University Cancer Institute found that supplementation with SelenoExcell(R), reduced serum PSA levels, a risk indicator for prostate cancer (El-Bayoumy et al, Cancer Epidemiology Vol. 11, 1459-1465, Nov., 2002). References to these and other studies can be found at the website, http://www.cypsystems.com, under the research matrix "Cancer" section of the home page.

Paul A. Willis, CEO & President of Cypress Systems, Inc. stated that, "Clearly we believe that the SELECT TRIAL should have included the standardized high-selenium yeast, which has been found effective in reducing cancer risk in animal studies and human clinical trials." High-selenium yeast is different from selenomethionine. It contains several different forms of organically-bound selenium in addition to selenomethionine.

According to Dr. Mark Whitacre, Cypress Systems' COO, "We suspect that the advantage of SelenoExcell(R) High-Selenium Yeast lies in its content of multiple forms of selenium, including some that are more direct acting in anti-carcinogenesis."

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Cypress Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
3. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
4. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
5. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
8. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
9. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 TapImmune,Inc. (TPIV), a ... and gene-based immunotherapeutics and vaccines for the treatment of cancer ... the 3rd Annual Growth Capital Expo to be ... at Caesars Palace in Las Vegas, Nevada.  The Company ... 4 th by Dr. John N. Bonfiglio ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of ... improve smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the ... to learn more about the options currently available to them and which ones might ...
(Date:4/29/2016)... , ... April 29, 2016 , ... For those who ... the meal to miss. That was among the many new lifestyle diet tips offered ... recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):